National Resilience, Inc. (Resilience), a technology-driven biomanufacturing leader dedicated to broadening access to complex medicines, today announced the expansion of its collaboration with Parvus ...

COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies designed ...

Drugs for metabolic diseases, vaccines and cancer therapies feature among new product launches this year that could top $1 billion in annual sales or be clinical "game changers" in the next five years ...

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug ...

Here are some of the drugs that are predicted to become blockbusters in the next few years, according to Clarivate's latest ...

Advancement in Nanoparticle-Based NIRF Probes for Precision Visualization in Oncology. Open Access Library Journal, 12, 1-14. doi: 10.4236/oalib.1112471 . Molecular imaging has introduced new ...

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 ...

The researcher has given an overview on the regulatory network of extracellular circRNAs in cancer and their impact on cancer drug resistance.

NanoImaging Services ("NIS"), the leading provider of cryo-electron microscopy ("cryo-EM") services for drug discovery and ...